BioSpace News Archive

A registered follow-on public offering by certain pre-IPO shareholders of 3,283,950 American depositary shares of I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, has priced on February 8, 2021 at a public offering price of US$54.0 per ADS.

The fund will create a permanent umbrella to develop initiatives to support researchers of color and increase diversity in cancer research and patient care

Lyell Immunopharma (“Lyell”), an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, today announced the appointment of Charlie Newton as Chief Financial Officer.

The National Kidney Foundation unveiled a new clinical tool for pediatric healthcare professionals to assess kidney disease progression in children and help provide more targeted care.

Continued access to leading innovation from Penn’s Center for Cellular Immunotherapies (CCI) Expanded rights to Penn cell manufacturing and platform technologies Exclusive rights to an additional CAR T-cell therapy product for multiple solid tumors

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s disease, today announced the presentation of favorable data from its clinical and drug development program for its lead candidate, Trappsol® Cyclo™.

Longeviti Neuro Solutions, a company advancing neurosurgery through the development of low-profile intracranial devices to address the functional and reconstructive needs of patients with neurological conditions, announced today the results of a study demonstrating that the InvisiShunt implant shows promising outcomes with a low complication rate for patients

Trxade Group, Inc. announced that the Company has appointed technology entrepreneur and industry thought leader James Ram to lead the Company’s newly launched MedCheks LLC subsidiary in its efforts to bring a Digital Health Passport to market - allowing the holder to display vaccination status and test results for travel or access to events and public facilities.

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ will be used in a longitudinal study of approximately 250 pediatric patients infected with SARS-CoV-2, the virus that causes COVID-19.

- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022